Disseminated adenovirus (AV) disease is associated with mortality rates of 6-60% among allogeneic stem cell transplant recipients. [1] [2] [3] Risk factors for AV infections in these patients include an unrelated or a T-cell depleted allogeneic transplant, alemtuzumab or irradiation in conditioning regimens, donor seropositive for AV, the presence of GVHD, concurrent immunosuppressive therapy.
2,4-7 Adenoviral infections usually occur during the first 3 months following stem cell transplantation, at a time when immunosuppression is maximal.
2,7 Treatment with cidofovir is not always active in disseminated AV infections. 8, 9 We report a case of disseminated AV infection developing more than 6 years after allogeneic hematopoietic stem cell transplantation.
In August 2006, a 26-year-old man was admitted after more than 6 years of a second allogeneic hematopoietic BMT with a 4-day history of fever, producing cough and diarrhea. He had been diagnosed with B-cell ALL in September 1995. CR was obtained and he underwent allogeneic BMT from an HLA identical sibling in January 1996. At month 18, post transplant, T-cell lymphopenia with low CD4 þ cell numbers (137/mm 3 ) and profound hypogammaglobulinemia persisted. In May 1999, he developed a persistent aplastic anemia. Viral serologies, including HIV, CMV, parvovirus B19, EBV, Herpesvirus 6 (HHV6) and adenovirus were all negative. In January 2000, he underwent a second transplantation with PBSC from the same donor. The conditioning regimen consisted in fludarabine and antithymocyte globulin. CYA and mycophenolate mofetil were given for GVHD prophylaxis. On day 20, EBV and CMV reactivations led to treatment with rituximab antibodies and ganciclovir. Late post transplant complications included hepatic nodular regenerative hyperplasia on a liver biopsy, several episodes of bronchopneumonia, rotavirus gastroenteritis and influenza virus infections. His CD4 þ T-cell count remained between 200 and 400/mm 3 associated with B cells lymphopenia predominating on memory cells CD27 þ , assessed at 2% of total B-cells (normal 23-49%) and g-globulin level was 0.6 g/l.
On admission, the patient had been off immunosuppressive treatment for more than 5 years. Clinical examination found a persistent fever at 39 1C despite broad-spectrum antibiotherapy (piperacillin-tazobactam and amikacin), low blood pressure (81/26 mm Hg), tachycardia (126/per min), respiratory crackles, diarrhea (four non-bloody, loose stools per day), rash and hepatomegaly. Total lymphocyte count was 550/mm 3 with only 8% CD4 þ T-cell (60/mm 3 ). Liver enzymes were elevated at twice the upper level of normal (ULN) on admission and raised to more than 10 ULN at day 3 (ALAT4ASAT). Alkaline phosphatase, bilirubin and C-reactive protein were also elevated. Blood, stool and urine cultures remained sterile. However, detection of adenovirus by quantitative real-time PCR was positive in plasma (47.6 log/ml), stools (4 log/ml), nasopharyngeal secretions (5.56 log/150 000 cells) and duodenal biopsy (4 log/150 000 cells). Genotyping analysis identified adenovirus group C infection. Other viruses (HBV, HCV, CMV, EBV, VZV, HSV and HHV6) were not detected. Evaluation by CT scan showed moderate bilateral pleural effusions, basal micronodules and bronchial thickening. Signs of chronic GVHD were present on intestinal biopsies. The diagnosis of disseminated AV infection prompted treatment with cidofovir, initiated two days after admission, at a weekly dose of 5 mg/kg during the first two weeks, followed by 5 mg/kg every two weeks, with a total of four injections. Prompt clinical improvement was observed following the first two injections with resolution of fever and pleural effusion, and improvement of diarrhea, hepatic cytolysis and inflammatory syndrome. The patient did not receive any treatment for chronic GVHD. Plasma adenovirus load as assessed by PCR decreased under cidofovir therapy to 3.59 log/ml one month after the last injection, and was undetectable (o2 log/ml) 3 months later ( Figure 1 ).
We report a unique case of disseminated adenovirus disease diagnosed more than 6 years after allogeneic BMT, with favorable outcome despite a very high initial plasma viral load. The patient was profoundly lymphopenic despite having discontinued all immunosuppressive treatment more than 5 years previously, probably because he underwent two allogeneic SCT.
Delayed lymphocyte recovery, especially a lymphocyte count less than 300/mm 3 , has been identified in adults as a risk factor for adenovirus disease. 7 A major role for CD4 þ cells in immunity against adenovirus infection has been reported in vitro. Depending on age, degree of MHC mismatch and presence of GVHD, recovery of normal T-cell number and function often does not occur within the first year following allogeneic SCT. Absence of GVHD also seems to allow an optimal reconstitution of adaptive immunity as GVHD, by direct toxicity to the thymic microenvironment, contributes to delayed thymic recovery as well as impaired peripheral expansion of mature T cell. 10 Moreover, production of IgG, depending on the availability of CD4 þ cell help is largely reduced by the presence of chronic extensive GVHD and this B-cell deficiency may often extend to 1-2 years following transplantation. In most studies, adenovirus infections generally developed within 3 months post transplant. 2, 7 In our patient, prompt diagnosis and rapid initiation of cidofovir therapy probably explain the good outcome. The usefulness of a rapid diagnosis of AV infection using real-time quantitative PCR has been stressed by Leruez-Ville et al. 11 In a few reports, decrease of plasma viral load with cidofovir therapy has been associated, as in our patient, with a favourable outcome and follow-up of plasma viral load is a good predictor of outcome. Letter to the Editor
